Myelodysplastic syndromes (MDS) anemia is a group of bone marrow disorders characterized by ineffective blood cell production, leading to low red blood cell counts, fatigue, and increased risk of progression to acute leukemia. It results from genetic mutations in hematopoietic stem cells that disrupt normal maturation of blood cells.
MDS anemia is not a single disease but a spectrum of conditions classified by the World Health Organization (WHO) based on blood cell morphology, genetic markers, and risk of transformation to acute myeloid leukemia (AML). The condition primarily affects older adults, with median onset around age 70, though rare cases occur in younger individuals.
Unlike iron-deficiency anemia or anemia due to chronic illness, MDS anemia stems from intrinsic defects in the bone marrow's ability to generate functional red blood cells. This leads to anemia that often resists standard treatments like iron supplements or erythropoietin therapy. Diagnosis requires peripheral blood smear analysis, bone marrow biopsy, and cytogenetic testing.
Bone marrow produces blood cells through a tightly regulated process involving hematopoietic stem cells. In MDS, mutations accumulate in these precursor cells, causing dysplasia-abnormal development-and premature cell death. As a result, mature red blood cells fail to form properly, leading to anemia.
Studies show that over 60% of MDS patients have chromosomal abnormalities detectable via karyotyping. Common changes include deletions in chromosome 5q (5q- syndrome), monosomy 7, and trisomy 8. These alterations disrupt genes involved in cell cycle control and apoptosis, allowing abnormal clones to outcompete healthy ones.
A 2022 study published in *Blood Advances* found that patients with complex karyotypes (three or more chromosomal abnormalities) had a median survival of just 18 months compared to 5 years in those with isolated 5q deletions. This highlights how genetic profiling directly influences prognosis and treatment decisions.
The WHO classifies MDS into five major subtypes based on the percentage of blasts in the bone marrow and the presence of specific morphological features. Each subtype correlates with distinct clinical behavior and response to therapy.
| Type | Blast Percentage | Key Features | Prognosis |
|---|---|---|---|
| Refractory Anemia (RA) | <5% | Low hemoglobin, normal platelets, no excess blasts | Median survival ~5 years |
| Refractory Anemia with Ring Sideroblasts (RARS) | <5% | Ring sideroblasts in bone marrow, low ferritin, normal iron stores | Best outcome among MDS subtypes |
| Refractory Cytopenia with Multilineage Dysplasia (RCMD) | <5% | Low counts in two or more blood lines (red, white, platelets) | Intermediate risk of AML transformation |
| Refractory Anemia with Excess Blasts (RAEB-1) | 5-9% | Early signs of blast accumulation, higher risk of progression | Median survival ~2 years |
| Refractory Anemia with Excess Blasts (RAEB-2) | 10-19% | Meets criteria for AML under WHO guidelines | High risk of rapid progression |
One non-obvious distinction is that RARS accounts for only 5-10% of MDS cases but has a better survival rate. This subtype is linked to mutations in the *SF3B1* gene, which is associated with ring sideroblasts-iron-laden mitochondria surrounding the nucleus in developing red blood cells.
Another key insight: patients with isolated 5q deletion (5q- syndrome) respond well to lenalidomide, a drug that targets the underlying molecular defect. Response rates exceed 60% in this subgroup, reducing transfusion dependence and improving quality of life. This targeted effect underscores why precise diagnosis matters.
MDS anemia is frequently mistaken for nutritional anemia, especially iron deficiency or vitamin B12 deficiency. However, unlike these conditions, MDS anemia persists despite adequate iron and vitamin levels. Blood tests often reveal normal serum iron, ferritin, and vitamin B12 in MDS patients.
Some assume MDS is always fatal or rapidly progresses to leukemia. This is incorrect. About 30% of patients with low-risk MDS live five years or longer without progressing to AML. Risk stratification using the International Prognostic Scoring System (IPSS-R) helps predict outcomes based on blast count, cytogenetics, and blood counts.
A common error is treating MDS anemia with iron supplementation. Iron overload can develop in patients requiring frequent blood transfusions, increasing oxidative stress and organ damage. The American Society of Hematology (ASH) recommends monitoring ferritin and liver iron concentration in transfused patients to avoid complications.
A 72-year-old man presented with persistent fatigue, dizziness, and pallor. His CBC showed hemoglobin 8.1 g/dL, mean corpuscular volume (MCV) 88 fL, and reticulocyte count 0.8%. Iron studies were normal. Bone marrow biopsy revealed 4% blasts and marked dysplasia in the erythroid lineage. Cytogenetic testing identified a del(5q) abnormality.
He was diagnosed with MDS-RAEB-1. After starting lenalidomide 10 mg daily, his hemoglobin rose to 12.5 g/dL within four months. He required no further transfusions and reported improved energy levels. This case illustrates how targeted therapy can reverse anemia in a subset of MDS patients.
During a follow-up visit, he experienced mild neutropenia, prompting dose reduction to 5 mg. His symptoms remained stable, and no progression to AML occurred over 24 months of monitoring. This outcome aligns with data from the MDS Clinical Trials Consortium showing 5q- patients achieve durable responses in over half of cases.
Unexplained fatigue, frequent infections, easy bruising, or petechiae may signal underlying blood disorders. If routine blood work shows low hemoglobin, low platelets, or low white blood cells, a referral to hematology is warranted.
Diagnostic pathways include peripheral smear review, bone marrow aspiration and biopsy, flow cytometry, and molecular testing for mutations such as *SF3B1*, *TET2*, and *ASXL1*. Early detection allows for timely intervention and better management of complications.
Understanding MDS anemia requires distinguishing it from other forms of anemia based on origin, genetics, and treatment response. Accurate classification guides therapy and improves long-term outcomes.